Back to search results

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Abroad (travel likely)RecruitingPHASE2

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Salehi Retina Institute, Huntington Beach, California, United States

    Contact: Study coordinator (Gillian Nguyen) · g.nguyen@retinasocal.com · 657-227-9496
    Contact: Principal Investigator (Hani Salehi-Had)

  • Retinal Consultants Medical Group Inc, Sacramento, California, United States

    Contact: Study coordinator (Daniel Ortiz) · ortizd@retinalmd.com · 916-339-3655
    Contact: Principal Investigator (Margaret Chang)

  • California Retina Consultants, Santa Barbara, California, United States

    Contact: Study coordinator (Muskaan Kaur Bal) · muskaanb@californiaretina.com · +1 805 963 1648
    Contact: Principal Investigator (Dante Pieramici)

  • Advanced Research LLC, Boynton Beach, Florida, United States

    Contact: Study coordinator (Alayka Reddy) · areddy@advancedresearchfl.com
    Contact: Principal Investigator (Drew Philip Bawcombe)

  • Advanced Research LLC, Deerfield Beach, Florida, United States

    Contact: Study coordinator (Isabella Villalonga) · ivillalonga@advancedresearchfl.com · 954-204-0052
    Contact: Principal Investigator (Shailesh Gupta)

  • Retina Vitreous Associates of Florida, St. Petersburg, Florida, United States

    Contact: Study coordinator (Logan Wilson) · lwilson@rvaf.com · 727-323-0077
    Contact: Principal Investigator (David Eichenbaum)

  • Opthamalic Consultants of Boston, Boston, Massachusetts, United States

    Contact: Study coordinator (Hanna Raymond) · hraymond@eyeboston.com · 617-314-2636
    Contact: Principal Investigator (Jeffrey S Heier)

  • NJ Retina, Toms River, New Jersey, United States

    Contact: Study coordinator (Andy Merino) · amerino@njretina.com · 732-906-1887
    Contact: Principal Investigator (Howard Fine)

  • New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Katy Tai) · ktai@nyee.edu · 212-979-4251
    Contact: Principal Investigator (Richard Rosen)

  • Columbia University Medical Center, New York, New York, United States

    Contact: Study coordinator (Sokleab Em) · se2389@cumc.columbia.edu · 212-305-6361
    Contact: Principal Investigator (Tongalp Tezel)

  • Erie Retina Research LLC, Erie, Pennsylvania, United States

    Contact: Study coordinator (Jade Horn) · jhorn@erieretinaresearch.com
    Contact: Principal Investigator (David Almeida)

  • Mid Atlantic Retina, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Angelique Ortiz) · asortiz@midatlanticretina.com · 800-331-6634
    Contact: Principal Investigator (Carl Regillo)

  • Retina Consultants TX Rsrch Ctr, Bellaire, Texas, United States

    Contact: Study coordinator (MaryGrace Powers) · marygrace.powers@retinaconsultantstexas.com · 713-524-3434
    Contact: Principal Investigator (David M Brown)

  • Retina Consultants of Houston PA, Houston, Texas, United States

    Contact: Study coordinator (Erin Shelato) · erin.shelato@retinaconsultantstexas.com
    Contact: Principal Investigator (Charles C Wykoff)

  • Retina Consultants of Texas, Katy, Texas, United States

    Contact: Study coordinator (Kymmia Majedi) · kymmia.majedi@retinaconsultantstexas.com
    Contact: Principal Investigator (Kenneth Fan)

  • Novartis Investigative Site, Albury, New South Wales, Australia

  • Novartis Investigative Site, Parramatta, New South Wales, Australia

  • Novartis Investigative Site, Strathfield, New South Wales, Australia

  • Novartis Investigative Site, East Melbourne, Victoria, Australia

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, London, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Lyon, Rhone, France

  • Novartis Investigative Site, Créteil, France

  • Novartis Investigative Site, Dijon, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Bonn, Germany

  • Novartis Investigative Site, Ludwigshafen, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Pécs, Baranya, Hungary

  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Florence, FI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site, Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Emanuelli Research and Development Center LLC, Arecibo, Puerto Rico

    Contact: Study coordinator (Diane Perez Perez) · dperez@erdpr.com · +1 787 879 7722
    Contact: Principal Investigator (Andres Emanuelli Anzalotta)

  • Novartis Investigative Site, Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Sant Cugat Del V, Barcelona, Spain

  • Novartis Investigative Site, Burjassot, Valencia, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Bristol, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)